| __timestamp | Intra-Cellular Therapies, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 504755000 |
| Thursday, January 1, 2015 | 18187286 | 838526000 |
| Friday, January 1, 2016 | 24758063 | 1177697000 |
| Sunday, January 1, 2017 | 23666957 | 1320433000 |
| Monday, January 1, 2018 | 30099855 | 1556200000 |
| Tuesday, January 1, 2019 | 64947625 | 1834800000 |
| Wednesday, January 1, 2020 | 186363444 | 1346000000 |
| Friday, January 1, 2021 | 272611040 | 1824900000 |
| Saturday, January 1, 2022 | 358782000 | 2115900000 |
| Sunday, January 1, 2023 | 409864000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses surged by over 400%, peaking at approximately $2.63 billion in 2023. This reflects their aggressive expansion and market penetration strategies. In contrast, Intra-Cellular Therapies, while starting with a modest $10 million in 2014, saw a staggering increase of nearly 3,900%, reaching around $410 million in 2023. This dramatic rise highlights their rapid growth and investment in administrative capabilities. These trends underscore the dynamic nature of the biotech sector, where strategic financial management can significantly impact a company's trajectory.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Grifols, S.A.
Regeneron Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. or Pharming Group N.V.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation